Home / ASCO Direct Highlights / ASCO Direct Highlights - South Carolina

ASCO Direct Highlights - South Carolina

ASCO-Direct-Gaillard-Center-400x230 Gaillard Center
95 Calhoun Street
Charleston, SC 29401
843.724.5212

On August 10, the South Carolina Oncology Society and Association of Community Cancer Centers present the highlights of the 2019 ASCO Annual Meeting through its licensed ASCO Direct™ Highlights meeting.

At this ASCO Direct™ Highlights meeting, attendees were able to:

  • Discover practice-changing scientific and educational updates which reflect the foremost research and strategies in oncology that will directly impact patient care.
  • Learn from leaders in the field, network with peers, and experience in-depth analysis and discussion that you can bring back to your colleagues and your cancer program or practice.

More details including speaker names and organizational affiliations will be posted in the coming weeks.

Download Agenda  Continuing Education Credits
 

Intended Audience

Multidisciplinary clinical cancer care team members including—but not limited to—medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.

Learning Objectives

Attendees of the ASCO Direct™ Highlights meeting gained insight to:

  • Review highlights of the advances in clinical and translational research presented at the 2019 ASCO® Annual Meeting
  • Identify emerging trends and strategies designed to improve the quality of survivorship care
  • Evaluate tools and resources in specific areas of cancer management that can be used to achieve effective cancer care delivery and improve the patient experience

Meeting Questions?
Contact ACCC at 301.984.9496, ext. 200 or email registration@accc-cancer.org.

Co-Hosts

South Carolina    logo-ACCC-200x80

Supporters

This activity is supported in part by educational grants from Astellas and Seattle Genetics, Celgene Corporation, Exelixis, Inc.,  Pfizer, Inc., and TESARO, Inc.